{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-105746","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2023-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.799203+00:00","generated_at":"2026-06-16T23:31:07.638021+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kura Oncology reports Phase 1 data for ziftomenib: 30% CR, 35% CRc in R/R NPM1-m AML at RP2D","bullets":["In 20 NPM1-m R/R AML patients at 600mg RP2D: CR rate 30%, composite CR (CRc) 35%, ORR 40%.","Median duration of CRc response 8.2 months; median OS 5.1 months with 8.0 months follow-up.","Safety: 85% had Grade ≥3 TEAEs; differentiation syndrome (any grade) 20%, Grade 3 DS 5%.","Patients heavily pretreated: median 2.5 prior therapies, 60% prior venetoclax, 15% prior SCT.","Registration-directed Phase 2 study of ziftomenib monotherapy in R/R NPM1-m AML now accruing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-105746","json":"https://secwatch.observer/filing/0001193125-23-105746.json","markdown":"https://secwatch.observer/filing/0001193125-23-105746.md","text":"https://secwatch.observer/filing/0001193125-23-105746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312523105746/0001193125-23-105746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312523105746/d467874d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T23:31:07.638021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}